Skip to content

13F-HR filed by BB BIOTECH AG

BB BIOTECH AG filed this 13F-HR for the quarter ended 2014-09-30, filed 2014-11-13, with 26 holding rows worth $2,459,443,000.

Accession
0000950123-14-011774
Filed
2014-11-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2014

A holdings report, 26 entries on the cover page, a total value of $2,459,443,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,459,442,000 with VALUE read as thousands by filing date, 13F file number 028-06964. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerBiotech Focus N.V. 028-11193
  • included managerBiotech Invest N.V. 028-11191
  • included managerBiotech Target N.V. 028-11189

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CELGENE CORP151020104COM3,889,298$368,628,000thousands by filing date
Gilead Sciences,Inc.375558103COM2,795,596$297,591,000thousands by filing date
ISIS PHARMACEUTICALS INC464330109COM6,636,526$257,696,000thousands by filing date
INCYTE CORP COM45337C102Stock4,301,867$211,007,000thousands by filing date
Vertex Pharmaceuticals Incorporated92532F100COM1,354,445$152,118,000thousands by filing date
MEDIVATION INC58501N101COM1,429,706$141,355,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM727,428$120,622,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM1,890,521$115,983,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK476,991$113,796,000thousands by filing date
PHARMACYCLICS INC716933106COM731,542$85,905,000thousands by filing date
REGENERON PHARMACEUTICALS COM75886F107Stock233,000$84,001,000thousands by filing date
SYNAGEVA BIOPHARMA CORP87159A103COM1,093,476$75,209,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock781,288$61,019,000thousands by filing date
HALOZYME THERAPEUTICS INC COM40637H109Stock6,430,532$58,518,000thousands by filing date
RADIUS HEALTH INC750469207COM NEW2,745,040$57,646,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM3,116,552$48,836,000thousands by filing date
RECEPTOS, INC.756207106COMMON STOCK636,773$39,550,000thousands by filing date
IMMUNOGEN INC45253H101COMMON STOCK3,165,816$33,526,000thousands by filing date
NOVAVAX INC670002104COMMON STOCK7,500,000$31,275,000thousands by filing date
INFINITY PHARMACEUTICALS INC45665G303COM2,320,737$31,144,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM558,188$25,319,000thousands by filing date
TESARO INC881569107COM704,582$18,967,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM1,279,340$12,768,000thousands by filing date
THERAVANCE INC88338T104COMMON STOCK743,244$12,702,000thousands by filing date
ENDOCYTE INC29269A102COM683,522$4,156,000thousands by filing date
CUBIST PHARMACEUTICALS INC229678123RIGHT 99/99/9999 ADDED876,273$105,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-14-011774this filing2014-11-13acceptance time not in the bulk data set